Mr. Chatterjee, served as CEO and MD of Mindtree from 2019 until its merger with L&T Infotech in November 2022, after which he led the newly formed LTIMindtree. Published - May 30, 2025 10:39 pm ...

Maryland medical expert highlights symptoms of adult autism as cases rise 01:26. Autism Spectrum Disorder (ASD) has long been associated with childhood diagnoses, but as new research shows a shift ...

A 16-year-old was arrested in connection to more than 100 vehicle break-ins earlier this month in Maryland. But it’s what happened afterward that left Laurel’s police chief so agitated.

Selim RF Hussain has resigned from the posts of managing director and chief executive officer (CEO) of BRAC Bank, effective from yesterday, according to a statement from the private lender.

The 2025 annual meeting of the Peripheral Nerve Society (PNS) takes place in Edinburgh, Scotland, from May 17-20. This year’s program includes eight special lectures, including the closing keynote.

Peter J. Wirsching, age 78, passed away May 6, 2025. Born January 21, 1947, to Raymond and Marie (Wheeler) Wirsching. Beloved husband of Carole Ann (Bednar) Wirsching; married May 31, 1969.

MD Anderson implements hiring pause after $43M loss, anxiety over Trump tariffs By Julian Gill , Staff writer April 28, 2025 MD Anderson Cancer Center is seen, Wednesday, Feb. 7, 2024, in Houston.

FORBES, Peter J. Of Braintree, MA, formerly of Quincy, MA, passed away on April 26, 2025 at the age of 66. Peter is survived by his wife of 34 ...

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts. Revisit part 1 of this interview, where Nowak ...

November 28, 1956 - April 17, 2025 Hinsdale, IL - Holly J. Humphrey, MD, MACP, led the Pritzker School of Medicine through a period of transformative growth that saw the school rise to a place ...

Continuous treatment led to greater changes in plasma amyloid-beta 42/40 levels, reported Christopher van Dyck, MD, of Yale University in New Haven, Connecticut, in a poster presented at the ...

“These findings provide the first evidence for a continued benefit of lecanemab and disease modification over the long term, out to 36 months,” Christopher van Dyck, MD, a researcher from Yale ...